medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Decay of Fc-dependent antibody functions after mild to moderate

2

COVID-19

3

Wen Shi Lee1â€ , Kevin John Selva1â€ , Samantha K. Davis1â€ , Bruce D. Wines2,3,4, Arnold

4

Reynaldi5, Robyn Esterbauer1, Hannah G. Kelly1, Ebene R. Haycroft1, Hyon-Xhi Tan1,

5

Jennifer A. Juno1, Adam K. Wheatley1,6, P. Mark Hogarth2,3,4, Deborah Cromer5, Miles

6

P. Davenport5, Amy W. Chung1*, Stephen J. Kent1,6,7*

7

â€ 

8
9

1

10

2

Immune Therapies Group, Burnet Institute, Melbourne, VIC, Australia.

11

3

Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.

12
13

4

14

5

15
16

6

17
18

7

These authors contributed equally.

Department of Microbiology and Immunology, University of Melbourne, at the Peter
Doherty institute for Infection and Immunity, Melbourne, VIC, Australia.

Department of Immunology and Pathology, Monash University, Melbourne, VIC,
Australia.
Kirby Institute, University of New South Wales, Kensington, NSW, Australia.

Australian Research Council Centre for Excellence in Convergent Bio-Nano Science
and Technology, University of Melbourne, Melbourne, VIC, Australia.
Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred
Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia.

19
20

*Corresponding authors. Email: awchung@unimelb.edu.au; skent@unimelb.edu.au.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

21

Abstract

22

The capacity of antibodies to engage with innate and adaptive immune cells via the

23

Fc region is important in preventing and controlling many infectious diseases, and is

24

likely critical in SARS-CoV-2 infection. The evolution of such antibodies during

25

convalescence from COVID-19 is largely unknown. We developed novel assays to

26

measure Fc-dependent antibody functions against SARS-CoV-2 spike (S)-expressing

27

cells in serial samples from a cohort of 53 subjects primarily with mild-moderate

28

COVID-19, out to a maximum of 149 days post-infection. We found that S-specific

29

antibodies capable of engaging dimeric FcÎ³RIIa and FcÎ³RIIIa decayed linearly over

30

time. S-specific antibody-dependent cellular cytotoxicity (ADCC) and antibody-

31

dependent phagocytosis (ADP) activity within plasma declined linearly as well, in line

32

with the decay of S-specific IgG. Although there was significant decay in S-specific

33

plasma ADCC and ADP activity, they remained readily detectable by all assays in 94%

34

of our cohort at the last timepoint studied, in contrast with neutralisation activity which

35

was only detectable in 70% of our cohort by the last timepoint. Our results suggest

36

that Fc effector functions such as ADCC and ADP could contribute to the durability of

37

SARS-CoV-2 immunity, particularly late in convalescence when neutralising

38

antibodies have waned. Understanding the protective potential of antibody Fc effector

39

functions is critical for defining the durability of immunity generated by infection or

40

vaccination.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

41

Introduction

42

Most individuals who recover from COVID-19 develop binding and neutralising

43

antibody responses against SARS-CoV-2 spike (S) protein (1, 2), with neutralising

44

antibody responses generally targeted to the receptor-binding domain (RBD) of S (3).

45

Passive transfer of neutralising monoclonal antibodies (mAbs) can protect animal

46

models from subsequent SARS-CoV-2 challenge (4-6), suggesting neutralisation is

47

likely to be a correlate of protection in humans (7). However, the duration of protection

48

from re-infection in humans conferred by neutralising antibodies is not known. Several

49

studies now show neutralising antibodies decline rapidly during early convalescence

50

(2, 8, 9), with the magnitude of the antibody response positively correlating with

51

disease severity (10, 11). Following mild COVID-19, many subjects mount modest

52

neutralising antibody responses that decline to undetectable levels within 60 days,

53

despite the maintenance of S- and RBD-specific IgG binding antibodies (10). Given

54

that reported cases of SARS-CoV-2 re-infection have been rare to date, it is likely that

55

immune responses beyond neutralisation contribute to SARS-CoV-2 protective

56

immunity. Apart from direct virus neutralisation, antibodies can also mediate antiviral

57

activity such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-

58

dependent phagocytosis (ADP) by engaging Fc gamma receptors (FcÎ³R) on NK cells

59

or phagocytes. Fc effector functions contribute to the prevention and control of other

60

viral infections including HIV-1, influenza and Ebola (12-14). Butler et al. recently

61

showed that SARS-CoV-2 RBD-specific antibodies within plasma could crosslink FcÎ³

62

receptors, and mediate ADP and antibody-dependent complement deposition (15).

63

Importantly, two recent challenge studies demonstrated that certain RBD-specific

64

mAbs rely on Fc effector functions to mediate protection against SARS-CoV-2 in mice

65

(16, 17).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

66
67

We previously reported that binding antibodies to SARS-CoV-2 S exhibit substantially

68

longer half-lives than the neutralising antibody response (8), suggesting that Fc-

69

mediated antibody function may extend the protective window beyond that inferred

70

from neutralising activity alone. At present, analyses of Fc-mediated functions of

71

SARS-CoV-2 antibodies within COVID-19 convalescent subjects have focussed upon

72

cross-sectional analyses or short-term longitudinal studies up to 1-2 months post-

73

symptom onset (15, 18, 19). We extend these findings and analyse Fc effector

74

functions mediated by S-specific antibodies in a cohort of 53 convalescent individuals

75

up to 149 days post-symptom onset. We developed novel functional assays using

76

SARS-CoV-2 S-expressing cells to comprehensively analyse plasma ADCC and ADP

77

activity against SARS-CoV-2 S. Our results show that plasma ADCC and ADP activity

78

decay over the first 4 months post-infection, mirroring the decline in S-specific IgG

79

titres. Importantly, however, S-specific antibodies capable of Fc-mediated antiviral

80

activity remain readily detectable in almost all donors out to 4 months post-infection,

81

even in donors whose neutralising antibody responses have waned to undetectable

82

levels. Consequently, S-specific IgG could potentially mediate Fc-dependent effector

83

functions that contribute to protection from SARS-CoV-2 infection even in the absence

84

of plasma neutralising activity.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

85

Results

86

Decay of dimeric FcÎ³R-binding S and RBD-specific antibodies

87

We collected repeated (2-4) longitudinal samples from a cohort of 53 subjects after

88

recovery from COVID-19 (Fig 1A, Table S1). The first sample was collected at a

89

median of 41 days post-symptom onset (IQR 36-48) while the last sample was

90

collected at a median of 123 days post-symptom onset (IQR 86-135). The engagement

91

of dimeric recombinant soluble FcÎ³RIIIa and FcÎ³RIIa proteins by antibodies mimics

92

the immunological synapse required for FcÎ³R activation of innate immune cells, and

93

is a surrogate measure of ADCC and ADP respectively (20, 21). To determine the

94

dynamics of Fc-mediated function in plasma samples over time, we measured the

95

capacity of dimeric FcÎ³RIIIa and FcÎ³RIIa receptors to engage antibodies specific for

96

SARS-CoV-2 S antigens (trimeric S, S1 or S2 subunits or the RBD; Table S2). Using

97

mixed-effects modelling, we assessed the fit of single-phase or two-phase decay in

98

FcÎ³R-binding between the timepoints analysed. We found that dimeric FcÎ³RIIIa

99

(V158)-binding antibodies against SARS-CoV-2 trimeric S and RBD both had single-

100

phase decay kinetics with half-lives (t1/2) of 175 and 95 days respectively (Fig. 1B-C).

101

Dimeric FcÎ³RIIa (H131) binding-antibodies against SARS-CoV-2 trimeric S and RBD

102

also decayed constantly with t1/2 of 175 and 74 days respectively. Kinetics of decay

103

for dimeric FcÎ³R-binding antibodies against S and RBD for the lower affinity

104

polymorphisms of FcÎ³RIIIa (F158) and FcÎ³RIIa (R131) were broadly similar to their

105

higher affinity counterparts (Fig. S1A), with dimeric FcÎ³R-binding antibodies against

106

RBD decaying faster than for S. Consistent with our previous report that S1-specific

107

IgG decays faster than S2-specific IgG(8), FcÎ³R binding activity with antibodies

108

against the S1 subunit decayed faster than that of S2 (FcÎ³RIIIa, t1/2 of 84 vs 227 days;

109

FcÎ³RIIa, t1/2 of 65 vs 317 days; Fig. S1B).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

110
111

Decay of S-specific ADCC

112

ADCC could play a role in eliminating cells infected with SARS-CoV-2. We generated

113

Ramos- and A549-derived cell lines as model target cells that stably express

114

membrane-localised S with either mOrange2 or luciferase reporters (Fig. S2A-B). The

115

capacity of plasma IgG to recognise S was measured in 36 subjects in our cohort who

116

had at least 60 days between the first and last visits (median of 89 days between first

117

and last visits; Table S1) and 8 seronegative controls. Using a Ramos cell line

118

expressing high levels of S (Ramos S-Orange) (Fig. S2C), we find IgG binding to cell-

119

surface displayed S proteins decayed significantly between the first and last visits

120

(p<0.0001; Fig. S2C) with a half-life of 97 days (Fig. S3). These results are consistent

121

with the decay of S-specific IgG titres we observed previously (8) and the decay of

122

dimeric FcÎ³R-binding antibodies against S in Fig 1B.

123
124

As a surrogate measure of ADCC, we next used FcÎ³RIIIa reporter cells to quantify the

125

capacity of S-specific antibodies in plasma to engage cell surface FcÎ³RIIIa and

126

activate downstream NF-ÎºB signalling (measured by induced nano-luciferase

127

expression in the FcÎ³RIIIa reporter cells) (Fig. 2A, Fig. S4A). FcÎ³RIIIa activity decayed

128

significantly over time (p<0.0001; Fig. 2C) with a half-life of 119 days (Fig. S3), and

129

was correlated with S-specific IgG titres measured using stably transduced cells or by

130

binding to dimeric FcÎ³RIIIa (Fig. 2D). To confirm antibody recognition could mediate

131

killing of S-expressing cells, we quantified the loss of cellular luciferase signal in

132

Ramos S-luciferase target cells in the presence of convalescent plasma and primary

133

human NK cells (Fig. 2B, Fig. S4B). S-specific ADCC decayed significantly over time

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

134

(p<0.0001; Fig. 2E) with a half-life of 105 days (Fig. S3), and correlated with both cell-

135

associated S-specific IgG and dimeric FcÎ³RIIIa-binding antibodies against S (Fig. 2F).

136
137

Decay of S-specific ADP

138

As has been suggested for SARS-CoV, ADP could play a role in eliminating antibody-

139

opsonised virions (22). We first used a well-established ADP assay (23) to measure

140

antibody-mediated uptake of S-conjugated fluorescent beads into THP-1 monocytes

141

(Fig. 3A; gating in Fig. S5A-B and optimisation in Fig. S6A-C). ADP of S-conjugated

142

beads was detected in all 36 subjects at the first time point studied but decayed

143

significantly over time (p<0.0001; Fig. 3C) with a half-life of 263 days (Fig. S3). ADP

144

of S-conjugated beads correlated with cell-associated S-specific IgG and S-specific

145

dimeric FcÎ³RIIa-binding antibodies (Fig. 3D).

146
147

In addition to uptake of antibody-opsonised virions, phagocytes could also potentially

148

mediate clearance of infected cells expressing SARS-CoV-2 S on the cell surface.

149

THP-1 cells have been shown to mediate both trogocytosis (sampling of plasma

150

membrane fragments from target cells that can lead to cell death) and phagocytosis

151

via antibody Fc-FcÎ³R interactions with target cells (24-26). As such, we measured the

152

FcÎ³R-dependent association of THP-1 cells with Ramos S-orange cells following

153

incubation with plasma from convalescent individuals or uninfected controls (Fig. 3B;

154

gating in Fig. S5C and optimisation in Fig. S6D-F). Association of THP-1 cells with

155

Ramos S-orange cells was detected in all subjects at the first time point but decayed

156

significantly over time (p<0.0001; Fig. 3E) with a half-life of 351 days (Fig. S3),

157

correlating with IgG binding to cell-associated S and S-specific dimeric FcÎ³RIIa-

158

binding antibodies (Fig. 3F).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

159
160

Cross-reactivity with HCoV S-specific antibodies

161

Cross-reactive antibodies between endemic human coronaviruses (HCoV) and SARS-

162

CoV-2 have been widely reported (27, 28), suggesting past exposure to HCoVs may

163

prime ADCC and ADP immunity against SARS-CoV-2. In addition, several studies

164

have shown back-boosting of antibodies against endemic human coronaviruses

165

(HCoV) following infection with SARS-CoV-2 (29, 30), likely due to the recall of pre-

166

existing B cell responses against conserved regions of S. We thus determined whether

167

IgG antibodies against S from four HCoV strains (OC43, HKU1, 229E and NL63)

168

(Table S2) were boosted in COVID-19 convalescent subjects compared to uninfected

169

healthy controls. We found that COVID-19 convalescent subjects had increased IgG

170

antibodies against S from the betacoronaviruses OC43 and HKU1 (that are more

171

closely related to SARS-CoV-2) at the first timepoint sampled compared to uninfected

172

controls (Fig S7), while there was no difference in IgG levels against S from the

173

alphacoronaviruses 229E and NL63. Correspondingly, the elevated IgG against OC43

174

and HKU1 S decayed over time while IgG against 229E and NL63 S remained stable

175

(Fig 4A). We then measured whether dimeric FcÎ³R-binding antibodies against HCoV

176

S antigens in COVID-19 convalescent individuals declined over time. Dimeric FcÎ³R-

177

binding antibodies against OC43 and HKU1 S antigens were much higher in COVID-

178

19 convalescent individuals than in healthy controls and decayed more rapidly over

179

time compared to that against 229E and NL63 (Fig. 4A, Fig S8A-C). While there was

180

an overall decay of dimeric FcÎ³R-binding antibodies against OC43 S (FcÎ³RIIIa t1/2 =

181

224, FcÎ³RIIa t1/2 = 171 days), this was largely due to a decay in antibodies against the

182

more conserved S2 subunit (FcÎ³RIIIa t1/2 = 229, FcÎ³RIIa t1/2 = 179 days) as FcÎ³R-

183

binding antibodies against the S1 subunit were not boosted and did not change

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

184

substantially over time (Fig. 4B-C). This was also the case for HKU1, where dimeric

185

FcÎ³R-binding antibodies against S decayed over time but antibodies against the S1

186

subunit did not change (Fig S8A).

187
188

Decay kinetics of S-specific antibodies, neutralisation and Fc effector functions

189

To compare the decay kinetics of S-specific antibodies, neutralisation and Fc effector

190

functions, we plotted the best fit decay slopes over time as a percentage of the

191

response measured at timepoint 1 (Fig. 5A). The best-fit decay slopes of S-specific

192

IgG and plasma neutralisation titres were obtained from a previous dataset that

193

encompass the same subjects analysed for dimeric FcÎ³R-binding antibodies and Fc

194

effector functions (8) (Fig. S3). The general decline in plasma S-specific IgG titres and

195

dimeric FcÎ³R-binding activity was similarly reflected in reductions in Fc effector

196

functions during convalescence from COVID-19. Importantly, Fc effector functions at

197

the last timepoint sampled were still readily detectable above baseline activity

198

observed in uninfected controls (97% for FcÎ³RIIIa activation, 94% for ADCC, 100% for

199

ADP and 100% for THP-1 association). This contrasted with plasma neutralisation

200

activity, which was detectable above background for only 70% of subjects (Fig. 5B).

201

The longer persistence of S-specific IgG and dimeric FcÎ³R-binding antibodies against

202

S has important implications as they may contribute to protection from SARS-CoV-2

203

infection following the decline of neutralising antibodies.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

204

Discussion

205

Using a multiplex bead array and novel assays measuring Fc effector functions against

206

SARS-CoV-2 S, we find that FcÎ³R-binding, ADCC and ADP activities of S-specific

207

antibodies decay during convalescence from COVID-19. The decline of plasma ADCC

208

and ADP activity correlated with the decay of S-specific IgG and FcÎ³R-binding

209

antibodies. Importantly, Fc effector functions were readily detectable above uninfected

210

controls in 94% of subjects for all assays at the last timepoint sampled, in sharp

211

contrast with neutralisation activity, which remained detectable above background for

212

only 70% of subjects. While neutralising antibodies are likely to form a correlate of

213

protection for SARS-CoV-2 (7), several studies find that neutralising antibodies in

214

convalescent donors with mild COVID-19 wane rapidly (2, 8, 9). The rapid decline of

215

plasma neutralisation activity in the early weeks following infection could potentially be

216

explained by the rapid decline of plasma IgM and IgA titres against S and RBD (19,

217

31), which substantially contribute to neutralisation of SARS-CoV-2 (32-34). Given the

218

relative scarcity of re-infection cases reported to date, it is likely that immune

219

responses beyond neutralisation, including antibody Fc effector functions and T cell

220

responses, contribute to long-term protection from SARS-CoV-2. Indeed, a recent

221

study demonstrated that cellular immunity in convalescent macaques, mainly CD8+ T

222

cells, contribute to protection against re-challenge after neutralising antibodies have

223

waned (22, 35).

224
225

Our results demonstrate that FcÎ³R-binding antibodies against betacoronaviruses

226

OC43 and HKU1 are much higher in COVID-19 convalescent individuals compared to

227

uninfected controls. This could either be due to the back-boosting of pre-existing HCoV

228

antibodies that are cross-reactive with SARS-CoV-2 (27, 28), or the de novo

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

229

generation of SARS-CoV-2 antibodies that are cross-reactive with conserved HCoV

230

epitopes. Cross-reactive S antibodies were largely directed against the more

231

conserved S2 subunit, in line with other reports (27, 28). A recent study found cross-

232

reactive binding and neutralising antibodies against SARS-CoV-2 S2 in uninfected

233

children and adolescents (27), suggesting prior infections with OC43 or HKU1 can

234

elicit cross-reactive antibodies against the S2 subunit of SARS-CoV-2 S. These

235

findings raise the interesting question of whether cross-reactive antibodies are

236

recalled rapidly during early SARS-CoV-2 infection and can contribute to Fc effector

237

functions against conserved epitopes within the S2 subunit. The presence of cross-

238

reactive S2-specific antibodies capable of mediating Fc effector functions in early

239

infection could potentially ameliorate disease symptoms and severity. Follow-up

240

studies to dissect the influence of S1 or S2 antibody epitope localisation on FcÎ³R

241

engagement and the impact on Fc effector functions are also warranted.

242
243

Initial concerns for antibody-dependent enhancement (ADE) of COVID-19 were driven

244

by the reported association of higher SARS-CoV-2 antibody titres with severe disease

245

(36). However, this could simply be the result of prolonged antigen exposure due to

246

higher viral loads. Importantly, Zohar et al. showed that in subjects with severe COVID-

247

19, those who survived had higher levels of S-specific antibodies and Fc-mediated

248

effector functions compared to those who died (31). Notably, numerous trials of

249

convalescent plasma (CP) therapy for COVID-19 have been safely conducted (37-39),

250

with no enhancement of disease reported to date (40-42). Since RBD-specific IgG1

251

antibodies in severe COVID-19 are more likely to have afucosylated Fc regions and

252

trigger hyper-inflammatory responses from monocytes and macrophages (43, 44),

253

there could be implications for ADE in people who are re-infected with SARS-CoV-2

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

254

after initial neutralising antibodies have waned but non-neutralising antibodies remain.

255

Excessive Fc-mediated effector functions and immune complex formation in the

256

absence of neutralisation could potentially trigger a hyper-inflammatory response and

257

lead to ADE of disease, as observed for RSV and measles infections (45, 46). While

258

ADE during re-infection remains only a theoretical risk, there have been two reported

259

cases of re-infection where the second infection resulted in worse disease (47, 48).

260

However, antibody levels after the first infection were not measured for one case (47)

261

and only IgM was detectable after the first infection for the second case (48), arguing

262

against Fc-mediated effector functions as the cause of increased pathogenicity.

263
264

Overall, we find that FcÎ³R-binding, ADCC and ADP antibody functions decay following

265

recovery from COVID-19 at a slower rate than serum neutralisation activity,

266

suggesting non-neutralising antibody responses elicited by infection or vaccination

267

may contribute to durable protection against SARS-CoV-2.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

268

Materials and methods

269

Cohort recruitment and sample collection

270

People who recovered from COVID-19 and healthy controls were recruited to provide

271

serial whole blood samples. Convalescent donors either had a PCR+ test during early

272

infection or clear exposure to SARS-CoV-2, and were confirmed to have SARS-CoV-

273

2 S- and RBD-specific antibodies via ELISA as previously reported (1).

274

Contemporaneous uninfected controls who did not experience any COVID-19

275

symptoms were also recruited and confirmed to be seronegative via ELISA. For all

276

subjects, whole blood was collected with sodium heparin or lithium heparin

277

anticoagulant. The plasma fraction was then collected and stored at -80ÂºC. A subset

278

of 36 donors with at least 60 days between the first and last visits were chosen to

279

proceed with the more labour-intensive functional ADCC and ADP assays. Plasma

280

was heat-inactivated at 56ÂºC for 30 minutes prior to use in functional assays.

281

Characteristics of the COVID-19 convalescent and uninfected donors are described

282

in Table S1. The study protocols were approved by the University of Melbourne

283

Human Research Ethics Committee (#2056689). All subjects provided written

284

informed consent in accordance with the Declaration of Helsinki.

285
286

Luminex bead-based multiplex assay

287

As previously described (49), a custom multiplex bead array was designed and

288

coupled with SARS-CoV-2 S trimer, S1 subunit (Sino Biological), S2 subunit (ACRO

289

Biosystems) and RBD (BEI Resources), as well as HCoV (OC43, HKU1, 229E, NL63)

290

S (Sino Biological) (Table S2). Tetanus toxoid (Sigma-Aldrich), influenza

291

hemagglutinin (H1Cal2009; Sino Biological) and SIV gp120 (Sino Biological) were also

292

included in the assay as positive and negative controls respectively. Antigens were

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

293

covalently coupled to magnetic carboxylated beads (Bio Rad) using a two-step

294

carbodiimide reaction and blocked with 0.1% BSA, before being resuspended and

295

stored in PBS 0.05% sodium azide till use.

296
297

Using the coupled beads, a custom CoV multiplex assay was formed to investigate

298

the dimeric recombinant soluble FcÎ³R-binding capacity of pathogen-specific

299

antibodies present in COVID-19 convalescent plasma samples and uninfected

300

controls (49). Briefly, 20Âµl of working bead mixture (1000 beads per bead region) and

301

20Âµl of diluted plasma (final dilution 1:200) were added per well and incubated

302

overnight at 4Â°C on a shaker. Different detectors were used to assess pathogen-

303

specific antibodies. Single-step detection was done using phycoerythrin (PE)-

304

conjugated mouse anti-human pan-IgG (Southern Biotech; 1.3Âµg/ml, 25Âµl/well). For

305

the detection of FcÎ³R-binding, recombinant soluble FcÎ³R dimers (higher affinity

306

polymorphisms FcÎ³RIIIa-V158 and FcÎ³RIIa-H131, lower affinity polymorphisms

307

FcÎ³RIIIa-F158 and FcÎ³RIIa-R131; 1.3Âµg/ml, 25Âµl/well) were first added to the beads,

308

washed, followed by the addition of streptavidin R-PE (Thermo Fisher Scientific).

309

Assays were read on the Flexmap 3D and performed in duplicates.

310
311

Cell lines

312

As target cells for the functional antibody assays, Ramos and A549 cells stably

313

expressing full-length SARS-CoV-2 S and the reporter proteins mOrange2 or

314

luciferase were generated by lentiviral transduction (Fig. S2A). To stain for S-

315

expression, transduced cells were incubated with convalescent plasma (1:100 dilution)

316

prior to staining with a secondary mouse anti-human IgG-APC antibody (1:200 dilution;

317

clone HP6017, BioLegend). S-luciferase cells were bulk sorted on high S expression

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

318

while S-orange cells were bulk sorted on high S- and mOrange2-expression. Following

319

a week of outgrowth, the bulk sorted cells were single-cell sorted to obtain clonal

320

populations of S-orange and S-luciferase cells (Fig. S2B). The Ramos cell lines were

321

grown in complete RPMI medium (10% fetal calf serum (FCS) with 1% penicillin

322

strepytomycin glutamine (PSG)) while the A549 cell lines were grown in complete

323

DMEM medium (10% FCS with 1% PSG).

324
325

FcÎ³RIIIa-NF-ÎºB-RE nanoluciferase reporter cells were used as effector cells for the

326

FcÎ³RIIIa activation assay. IIA1.6 cells expressing the Fc receptor gamma subunit

327

(FcR-Î³) were maintained in RPMI containing 10% FCS, 2.5 mM L-glutamine, 55 ÂµM

328

2-mercaptoethanol, 100 units penicillin and 100 units streptomycin (Sigma Aldrich).

329

These were further transduced as described previously (50) using a FcÎ³RIIIa V158

330

cDNA in pMX-neo and the packaging line Phoenix. IIA1.6/FcR-Î³/FcÎ³RIIIa V158 cells

331

were transfected with a NF-ÎºB response element driven nanoluciferase (NanoLuc)

332

reporter

333

nucleofection (Amaxa Kit T, Lonza) and selected in the presence of 200 Âµg/ml

334

hygromycin. Reporter cells were maintained in media containing 400 Âµg/ml neomycin

335

and 50 Âµg/ml hygromycin (ThermoFisher).

construct

(pNL3.2.NF-ÎºB-RE[NlucP/NF-ÎºB-RE/Hygro]

(Promega)

by

336
337

THP-1 monocytes (ATCC) were cultured in complete RPMI medium and maintained

338

below a cell density of 0.3Ã—106/ml. Flow cytometry was used to confirm stable

339

expression of FcÎ³RIIa (CD32), FcÎ³RI (CD64) and FcÎ±R (CD89) on THP-1 monocytes

340

prior to use in assays.

341
342

FcÎ³RIIIa activation assay

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

343

A549 S-orange cells were plated (2Ã—105/ml, 100 Âµl/well) in 96-well white flat-bottom

344

plates (Corning). The next day, COVID-19 convalescent and uninfected plasma were

345

serially diluted and 50 Âµl aliquots transferred to the aspirated A549 S-orange cells and

346

incubated at 37ÂºC, 60 min, 5% CO2. Unbound antibody was removed by aspirating the

347

wells and refilling with RPMI (200 Âµl) four times. FcÎ³RIIIa-NF-ÎºB-RE nanoluciferase

348

reporter cells (4 x 105/ml, 50 Âµl/well) were added to the aspirated wells containing the

349

opsonised A549 S-orange cells. After incubation (370C, 4h, 5%CO2) cells were lysed

350

by adding 50 Âµl/well of 10 mM Tris-pH 7.4, containing 5 mM EDTA, 0.5 mM DTT, 0.2%

351

Igepal CA-630 (Sigma Aldrich), and Nano-Glo luciferase assay substrate (1:1000).

352

Induction of nanoluciferase was measured using a 1s read on a Clariostar Optima

353

plate reader (BMG Labtech) with background luminescence from control wells without

354

agonist subtracted from test values.

355
356

Luciferase-based ADCC assay

357

A luciferase-based ADCC assay was performed to examine ADCC against S-

358

expressing cells. NK cells from healthy donors were first enriched from freshly isolated

359

PBMCs using the EasySep Human NK Cell Enrichment Kit (Stemcell Technologies).

360

In a 96-well V-bottom cell culture plate, purified NK cells (20,000/well) were mixed with

361

Ramos S-luciferase cells (5,000/well) in the presence or absence of plasma from

362

convalescent or uninfected donors at 1:100, 1:400 and 1:1600 dilutions. Each

363

condition was tested in duplicate and â€œno plasmaâ€ and â€œtarget cell onlyâ€ controls were

364

included. Cells were centrifuged at 250g for 4 min prior to a 4-hour incubation at 37ÂºC

365

with 5% CO2. Cells were then washed with PBS and lysed with 25Âµl of passive lysis

366

buffer (Promega). Cell lysates (20Âµl) were transferred to a white flat-bottom plate and

367

developed with 30Âµl of britelite plus luciferase reagent (Perkin Elmer). Luminescence

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

368

was read using a FLUOstar Omega microplate reader (BMG Labtech). The relative

369

light units (RLU) measured were used to calculate %ADCC with the following formula:

370

(â€œno plasma controlâ€ â€“ â€œplasma sampleâ€) Ã· â€œtarget cell only controlâ€ Ã— 100. For each

371

plasma sample, %ADCC was plotted against log10(plasma dilution-1) and the area

372

under curve (AUC) was calculated using Graphpad Prism.

373
374

Bead-based THP-1 ADP assay

375

To examine ADP mediated by COVID-19 convalescent plasma, a previously published

376

bead-based ADP assay was adapted for use in the context of SARS-CoV-2 (23).

377

SARS-CoV-2 S trimer was biotinylated using EZ-Link Sulfo-NHS-LC biotinylation kit

378

(Thermo Scientific) with 20mmol excess according to manufacturerâ€™s instructions and

379

buffer exchanged using 30kDa Amicon centrifugal filters (EMD millipore) to remove

380

free biotin. The binding sites of 1Î¼m fluorescent NeutrAvidin Fluospheres beads

381

(Invitrogen) were coated with biotinylated S at a 1:3 ratio overnight at 4Â°C. S-

382

conjugated beads were washed four times with 2% BSA/PBS to remove excess

383

antigen and incubated with plasma (1:100 dilution) for 2 hours at 37ÂºC in a 96-well U-

384

bottom plate (see Fig. S6 for optimisation). THP-1 monocytes (10,000/well) were then

385

added to opsonized beads and incubated for 16 hours under cell culture conditions.

386

Cells were fixed with 2% formaldehyde and acquired on a BD LSR Fortessa with a

387

HTS. The data was analyzed using FlowJo 10.7.1 (see Fig. S5 for gating strategy) and

388

a phagocytosis score was calculated as previously described (51) using the formula:

389

(%bead-positive cells Ã— mean fluorescent intensity)/103. To account for non-specific

390

uptake of S-conjugated beads, the phagocytosis scores for each plasma sample were

391

subtracted with that of the â€œno plasmaâ€ control.

392

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

393

Cell-based THP-1 association assay

394

To assess the capacity of THP-1 monocytes to associate with S-expressing target

395

cells via Ab-FcÎ³R interactions, an assay using THP-1 cells as effectors and Ramos S-

396

orange cells as targets was performed. THP-1 monocytes were first stained with

397

CellTraceTM Violet (CTV) (Life Technologies) as per manufacturerâ€™s instructions. In a

398

96-well V-bottom cell culture plate, Ramos S-orange cells (10,000/well) were

399

incubated with plasma from convalescent or uninfected donors (1:2700 dilution) for 30

400

minutes (see Fig. S6 for optimisation). Opsonised Ramos S-orange cells were then

401

washed prior to co-culture with CTV-stained THP-1 monocytes (10,000/well) for 1 hour

402

at 37ÂºC with 5% CO2. After the incubation, cells were washed with PBS, fixed with 2%

403

formaldehyde and acquired using the BD LSR Fortessa with a high-throughput

404

sampler attachment (HTS). The data was analyzed using FlowJo 10.7.1 (see Fig. S5

405

for gating strategy). The percentage of Ramos S-orange cells associated with THP-1

406

monocytes (% association) was measured for each plasma sample and background-

407

subtracted with the â€œno plasmaâ€ control.

408
409

Decay rate estimation

410

The decay rate was estimated by fitting a linear mixed effect model for each response

411

variable (yij for subject i at timepoint j) as a function of days post-symptom onset and

412

assay replicate (as a binary categorical variable). The model can be written as below:

413

ð‘¦"# = ð›½& + ð‘&" + ð›½) ð‘…"# + ð›½+ ð‘¡"# + ð‘+" ð‘¡"# â€“ for a model with a single slope; and

414

ð‘¦"# = ð›½& + ð‘&" + ð›½) ð‘…"# + ð›½+ ð‘¡"# + ð‘+" ð‘¡"# + ð›½- ð‘ "# + ð‘-" ð‘ "# â€“ for a model with two different

415

slopes, in which:

416

ð‘ "# = /

0, ð‘¡"# < ð‘‡&
ð‘¡"# âˆ’ ð‘‡& , ð‘¡"# â‰¥ ð‘‡&.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

417

The parameter ð›½& is a constant (intercept), and ð‘&" is a subject-specific adjustment to

418

the overall intercept. The slope parameter ð›½+ is a fixed effect to capture the decay

419

slope before ð‘‡& (as a fixed parameter, 70 days); which also has a subject-specific

420

random effect ð‘+" . To fit a model with two different decay rates, an extra parameter ð›½-

421

(with a subject-specific random effect ð‘-" ) was added to represent the difference

422

between the two slopes. Assay variability between replicates (only for HCoV response

423

variables) was modelled as a single fixed effect ð›½) , in which we coded the replicate as

424

a binary categorical variable ð‘…"# . The random effect was assumed to be normally

425

distributed with zero mean and variance ð›¿.

426
427

We fitted the model to log-transformed data of various response variables, and we

428

censored the data from below if it was less than the threshold for detection. The

429

response variables had background levels subtracted by taking the mean of all the

430

background values, and the threshold for detection was set at two standard deviations

431

of the background responses. The model was fitted by using lmec library in R, using

432

the ML algorithm to fit for the fixed effects. We also tested if the response variables

433

can be fitted better by using a single or two different decay slopes (likelihood ratio test

434

â€“ based on the likelihood value and the difference in the number of parameters). These

435

analyses were carried out in R: A language and environment for statistical computing

436

version 4.0.2.

437
438

Statistics

439

Statistical analyses were performed with Graphpad Prism 8. Correlations between

440

functional ADCC and ADP responses with cell-associated S-specific IgG and FcÎ³R-

441

binding S-specific antibodies were assessed using the non-parametric Spearman test.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

442

Comparisons of functional ADCC and ADP responses between first and last visits

443

were performed using the Wilcoxon signed-rank test. Comparisons between

444

uninfected individuals and COVID-19 convalescent individuals were performed using

445

the Mann-Whitney test.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

446

References

447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494

1.

2.

3.

4.

5.

6.

7.

8.

J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R.
Esterbauer, H. E. Kent, C. J. Batten, F. L. Mordant, N. A. Gherardin, P. Pymm,
M. H. Dietrich, N. E. Scott, W. H. Tham, D. I. Godfrey, K. Subbarao, M. P.
Davenport, S. J. Kent, A. K. Wheatley, Humoral and circulating follicular helper
T cell responses in recovered patients with COVID-19. Nat Med 26, 1428-1434
(2020).
A. Wajnberg, F. Amanat, A. Firpo, D. R. Altman, M. J. Bailey, M. Mansour, M.
McMahon, P. Meade, D. R. Mendu, K. Muellers, D. Stadlbauer, K. Stone, S.
Strohmeier, V. Simon, J. Aberg, D. L. Reich, F. Krammer, C. Cordon-Cardo,
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
Science, (2020).
L. Piccoli, Y. J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M.
Beltramello, C. Silacci-Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton,
S. Jaconi, B. Guarino, A. Minola, F. Zatta, N. Sprugasci, J. Bassi, A. Peter, A.
De Marco, J. C. Nix, F. Mele, S. Jovic, B. F. Rodriguez, S. V. Gupta, F. Jin, G.
Piumatti, G. Lo Presti, A. F. Pellanda, M. Biggiogero, M. Tarkowski, M. S.
Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithey, D. Hong, V. Lepori,
E. Albanese, A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva,
G. Snell, F. Sallusto, K. Fink, H. W. Virgin, A. Lanzavecchia, D. Corti, D. Veesler,
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell
183, 1024-1042 e1021 (2020).
T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. T. He, O. Limbo, C.
Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J.
Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A.
Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E.
Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D.
R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and
protection from disease in a small animal model. Science, (2020).
L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F. Chan, V.
Sahi, A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen,
K. Y. Yuen, P. D. Kwong, J. G. Sodroski, M. T. Yin, Z. Sheng, Y. Huang, L.
Shapiro, D. D. Ho, Potent neutralizing antibodies against multiple epitopes on
SARS-CoV-2 spike. Nature 584, 450-456 (2020).
A. Baum, D. Ajithdoss, R. Copin, A. Zhou, K. Lanza, N. Negron, M. Ni, Y. Wei,
K. Mohammadi, B. Musser, G. S. Atwal, A. Oyejide, Y. Goez-Gazi, J. Dutton,
E. Clemmons, H. M. Staples, C. Bartley, B. Klaffke, K. Alfson, M. Gazi, O.
Gonzalez, E. Dick, Jr., R. Carrion, Jr., L. Pessaint, M. Porto, A. Cook, R. Brown,
V. Ali, J. Greenhouse, T. Taylor, H. Andersen, M. G. Lewis, N. Stahl, A. J.
Murphy, G. D. Yancopoulos, C. A. Kyratsous, REGN-COV2 antibodies prevent
and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science,
(2020).
A. Addetia, K. H. D. Crawford, A. Dingens, H. Zhu, P. Roychoudhury, M. L.
Huang, K. R. Jerome, J. D. Bloom, A. L. Greninger, Neutralizing Antibodies
Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel
Outbreak with a High Attack Rate. J Clin Microbiol 58, (2020).
A. K. Wheatley, J. A. Juno, J. J. Wang, K. J. Selva, A. Reynaldi, H.-X. Tan, W.
S. Lee, K. M. Wragg, H. G. Kelly, R. Esterbauer, S. K. Davis, H. E. Kent, F. L.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543

9.

10.

11.

12.
13.
14.
15.

16.

17.

Mordant, T. E. Schlub, D. L. Gordon, D. S. Khoury, K. Subbarao, D. Cromer, T.
P. Gordon, A. W. Chung, M. P. Davenport, S. J. Kent, Evolution of immunity to
SARS-CoV-2. medRxiv, 2020.2009.2009.20191205 (2020).
K. H. D. Crawford, A. S. Dingens, R. Eguia, C. R. Wolf, N. Wilcox, J. K. Logue,
K. Shuey, A. M. Casto, B. Fiala, S. Wrenn, D. Pettie, N. P. King, A. L. Greninger,
H. Y. Chu, J. D. Bloom, Dynamics of neutralizing antibody titers in the months
after SARS-CoV-2 infection. J Infect Dis, (2020).
J. Seow, C. Graham, B. Merrick, S. Acors, S. Pickering, K. J. A. Steel, O.
Hemmings, A. O'Byrne, N. Kouphou, R. P. Galao, G. Betancor, H. D. Wilson,
A. W. Signell, H. Winstone, C. Kerridge, I. Huettner, J. M. Jimenez-Guardeno,
M. J. Lista, N. Temperton, L. B. Snell, K. Bisnauthsing, A. Moore, A. Green, L.
Martinez, B. Stokes, J. Honey, A. Izquierdo-Barras, G. Arbane, A. Patel, M. K.
I. Tan, L. O'Connell, G. O'Hara, E. MacMahon, S. Douthwaite, G. Nebbia, R.
Batra, R. Martinez-Nunez, M. Shankar-Hari, J. D. Edgeworth, S. J. D. Neil, M.
H. Malim, K. J. Doores, Longitudinal observation and decline of neutralizing
antibody responses in the three months following SARS-CoV-2 infection in
humans. Nat Microbiol, (2020).
A. T. Huang, B. Garcia-Carreras, M. D. T. Hitchings, B. Yang, L. C. Katzelnick,
S. M. Rattigan, B. A. Borgert, C. A. Moreno, B. D. Solomon, L. Trimmer-Smith,
V. Etienne, I. Rodriguez-Barraquer, J. Lessler, H. Salje, D. S. Burke, A.
Wesolowski, D. A. T. Cummings, A systematic review of antibody mediated
immunity to coronaviruses: kinetics, correlates of protection, and association
with severity. Nat Commun 11, 4704 (2020).
S. Bournazos, F. Klein, J. Pietzsch, M. S. Seaman, M. C. Nussenzweig, J. V.
Ravetch, Broadly neutralizing anti-HIV-1 antibodies require Fc effector
functions for in vivo activity. Cell 158, 1243-1253 (2014).
D. J. DiLillo, P. Palese, P. C. Wilson, J. V. Ravetch, Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection. J
Clin Invest 126, 605-610 (2016).
S. Bournazos, D. J. DiLillo, A. J. Goff, P. J. Glass, J. V. Ravetch, Differential
requirements for FcgammaR engagement by protective antibodies against
Ebola virus. Proc Natl Acad Sci U S A 116, 20054-20062 (2019).
S. E. Butler, A. R. Crowley, H. Natarajan, S. Xu, J. A. Weiner, J. Lee, W. F.
Wieland-Alter, R. I. Connor, P. F. Wright, M. E. Ackerman, Features and
Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2
Convalescent Individuals. medRxiv, 2020.2008.2005.20168971 (2020).
A. Schafer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos,
F. Schmidt, R. M. Maison, A. Gazumyan, D. R. Martinez, R. S. Baric, D. F.
Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, R. A. Bowen, M. C.
Nussenzweig, T. P. Sheahan, Antibody potency, effector function, and
combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp
Med 218, (2021).
C. E. Z. Chan, S. G. K. Seah, D. H. Chye, S. Massey, M. Torres, A. P. C. Lim,
S. K. K. Wong, J. J. Y. Neo, P. S. Wong, J. H. Lim, G. S. L. Loh, D. L. Wang, J.
D. Boyd-Kirkup, S. Guan, D. Thakkar, G. H. Teo, K. Purushotorman, P. E.
Hutchinson, B. E. Young, D. C. Lye, J. G. Low, P. A. MacAry, H. Hentze, V. S.
Prativadibhayankara, K. Ethirajulu, D. Oâ€™Connell, J. Comer, C.-T. K. Tseng, A.
D. T. Barrett, P. J. Ingram, T. Brasel, B. J. Hanson, The Fc-mediated effector
functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592

18.

19.

20.
21.

22.

23.

24.

25.

26.
27.

an early convalescent COVID-19 patient, are essential for the optimal
therapeutic efficacy of the antibody. bioRxiv, 2020.2010.2026.355107 (2020).
H. Natarajan, A. R. Crowley, S. E. Butler, S. Xu, J. A. Weiner, E. M. Bloch, K.
Littlefield, W. Wieland-Alter, R. I. Connor, P. F. Wright, S. E. Benner, T. S.
Bonny, O. Laeyendecker, D. J. Sullivan, S. Shoham, T. Quinn, H. B. Larman,
A. Casadevall, A. Pekosz, A. Redd, A. A. Tobian, M. E. Ackerman, SARS-CoV2 antibody signatures robustly predict diverse antiviral functions relevant for
convalescent plasma therapy. medRxiv, 2020.2009.2016.20196154 (2020).
J. Dufloo, L. Grzelak, I. Staropoli, Y. Madec, L. Tondeur, F. Anna, S. Pelleau,
A. Wiedemann, C. Planchais, J. Buchrieser, R. Robinot, M.-N. Ungeheuer, H.
Mouquet, P. Charneau, M. White, Y. LÃ©vy, B. Hoen, A. Fontanet, O. Schwartz,
T. Bruel, Asymptomatic and symptomatic SARS-CoV-2 infections elicit
polyfunctional antibodies. medRxiv, 2020.2011.2012.20230508 (2020).
B. D. Wines, H. A. Vanderven, S. E. Esparon, A. B. Kristensen, S. J. Kent, P.
M. Hogarth, Dimeric FcgammaR Ectodomains as Probes of the Fc Receptor
Function of Anti-Influenza Virus IgG. J Immunol 197, 1507-1516 (2016).
F. Ana-Sosa-Batiz, A. P. R. Johnston, P. M. Hogarth, B. D. Wines, I. Barr, A. K.
Wheatley, S. J. Kent, Antibody-dependent phagocytosis (ADP) responses
following trivalent inactivated influenza vaccination of younger and older adults.
Vaccine 35, 6451-6458 (2017).
F. Yasui, M. Kohara, M. Kitabatake, T. Nishiwaki, H. Fujii, C. Tateno, M. Yoneda,
K. Morita, K. Matsushima, S. Koyasu, C. Kai, Phagocytic cells contribute to the
antibody-mediated elimination of pulmonary-infected SARS coronavirus.
Virology 454-455, 157-168 (2014).
M. E. Ackerman, B. Moldt, R. T. Wyatt, A. S. Dugast, E. McAndrew, S. Tsoukas,
S. Jost, C. T. Berger, G. Sciaranghella, Q. Liu, D. J. Irvine, D. R. Burton, G.
Alter, A robust, high-throughput assay to determine the phagocytic activity of
clinical antibody samples. J Immunol Methods 366, 8-19 (2011).
P. V. Beum, D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, R. P. Taylor,
Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells
Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes. The Journal
of Immunology 181, 8120-8132 (2008).
S. Daubeuf, M. A. Lindorfer, R. P. Taylor, E. Joly, D. Hudrisier, The Direction of
Plasma Membrane Exchange between Lymphocytes and Accessory Cells by
Trogocytosis Is Influenced by the Nature of the Accessory Cell. The Journal of
Immunology 184, 1897-1908 (2010).
S. I. Richardson, C. Crowther, N. N. Mkhize, L. Morris, Measuring the ability of
HIV-specific antibodies to mediate trogocytosis. J Immunol Methods 463, 7183 (2018).
K. W. Ng, N. Faulkner, G. H. Cornish, A. Rosa, R. Harvey, S. Hussain, R. Ulferts,
C. Earl, A. G. Wrobel, D. J. Benton, C. Roustan, W. Bolland, R. Thompson, A.
Agua-Doce, P. Hobson, J. Heaney, H. Rickman, S. Paraskevopoulou, C. F.
Houlihan, K. Thomson, E. Sanchez, G. Y. Shin, M. J. Spyer, D. Joshi, N.
Oâ€™Reilly, P. A. Walker, S. Kjaer, A. Riddell, C. Moore, B. R. Jebson, M.
Wilkinson, L. R. Marshall, E. C. Rosser, A. Radziszewska, H. Peckham, C.
Ciurtin, L. R. Wedderburn, R. Beale, C. Swanton, S. Gandhi, B. Stockinger, J.
McCauley, S. J. Gamblin, L. E. McCoy, P. Cherepanov, E. Nastouli, G.
Kassiotis, Preexisting and de novo humoral immunity to SARS-CoV-2 in
humans. Science, eabe1107 (2020).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

G. Song, W.-t. He, S. Callaghan, F. Anzanello, D. Huang, J. Ricketts, J. L.
Torres, N. Beutler, L. Peng, S. Vargas, J. Cassell, M. Parren, L. Yang, C.
Ignacio, D. M. Smith, J. E. Voss, D. Nemazee, A. B. Ward, T. Rogers, D. R.
Burton, R. Andrabi, Cross-reactive serum and memory B cell responses to
spike protein in SARS-CoV-2 and endemic coronavirus infection. bioRxiv,
2020.2009.2022.308965 (2020).
T. Aydillo, A. Rombauts, D. Stadlbauer, S. Aslam, G. Abelenda-Alonso, A.
Escalera, F. Amanat, K. Jiang, F. Krammer, J. Carratala, A. GarcÃ­a-Sastre,
Antibody Immunological Imprinting on COVID-19 Patients. medRxiv,
2020.2010.2014.20212662 (2020).
B. M. Westerhuis, M. Aguilar-Bretones, M. P. Raadsen, E. de Bruin, N. M. A.
Okba, B. L. Haagmans, T. Langerak, H. Endeman, J. P. C. van den Akker, D.
A. M. P. J. Gommers, E. C. M. van Gorp, B. H. G. Rockx, M. P. G. Koopmans,
G. P. van Nierop, Severe COVID-19 patients display a back boost of seasonal
coronavirus-specific antibodies. medRxiv, 2020.2010.2010.20210070 (2020).
T. Zohar, C. Loos, S. Fischinger, C. Atyeo, C. Wang, M. D. Slein, J. Burke, J.
Yu, J. Feldman, B. M. Hauser, T. Caradonna, A. G. Schmidt, Y. Cai, H. Streeck,
E. T. Ryan, D. H. Barouch, R. C. Charles, D. A. Lauffenburger, G. Alter,
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2
Mortality. Cell, (2020).
R. Gasser, M. Cloutier, J. PrÃ©vost, C. Fink, Ã‰. Ducas, S. Ding, N. Dussault, P.
Landry, T. Tremblay, A. Laforce-Lavoie, A. Lewin, G. Beaudoin-BussiÃ¨res, A.
Laumaea, H. Medjahed, C. Larochelle, J. Richard, G. A. Dekaban, J. D.
Dikeakos, R. Bazin, A. Finzi, Major role of IgM in the neutralizing activity of
convalescent plasma against SARS-CoV-2. bioRxiv, 2020.2010.2009.333278
(2020).
Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M.
Cipolla, H.-H. Hoffmann, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E.
Michailidis, D. F. Robbiani, A. Gazumyan, C. M. Rice, T. Hatziioannou, P. D.
Bieniasz, M. Caskey, M. C. Nussenzweig, Enhanced SARS-CoV-2
neutralization by dimeric IgA. Science Translational Medicine, eabf1555 (2020).
D. Sterlin, A. Mathian, M. Miyara, A. Mohr, F. Anna, L. ClaÃ«r, P. Quentric, J.
Fadlallah, H. Devilliers, P. Ghillani, C. Gunn, R. Hockett, S. Mudumba, A.
Guihot, C.-E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T. Bruel, O. Schwartz, J.M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amoura, G.
Gorochov, IgA dominates the early neutralizing antibody response to SARSCoV-2. Science Translational Medicine, eabd2223 (2020).
W. He, C. J. Chen, C. E. Mullarkey, J. R. Hamilton, C. K. Wong, P. E. Leon, M.
B. Uccellini, V. Chromikova, C. Henry, K. W. Hoffman, J. K. Lim, P. C. Wilson,
M. S. Miller, F. Krammer, P. Palese, G. S. Tan, Alveolar macrophages are
critical for broadly-reactive antibody-mediated protection against influenza A
virus in mice. Nat Commun 8, 846 (2017).
J. Zhao, Q. Yuan, H. Wang, W. Liu, X. Liao, Y. Su, X. Wang, J. Yuan, T. Li, J.
Li, S. Qian, C. Hong, F. Wang, Y. Liu, Z. Wang, Q. He, Z. Li, B. He, T. Zhang,
Y. Fu, S. Ge, L. Liu, J. Zhang, N. Xia, Z. Zhang, Antibody responses to SARSCoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis, (2020).
K. Duan, B. Liu, C. Li, H. Zhang, T. Yu, J. Qu, M. Zhou, L. Chen, S. Meng, Y.
Hu, C. Peng, M. Yuan, J. Huang, Z. Wang, J. Yu, X. Gao, D. Wang, X. Yu, L.
Li, J. Zhang, X. Wu, B. Li, Y. Xu, W. Chen, Y. Peng, Y. Hu, L. Lin, X. Liu, S.
Huang, Z. Zhou, L. Zhang, Y. Wang, Z. Zhang, K. Deng, Z. Xia, Q. Gong, W.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692

38.

39.

40.

41.

42.

43.

44.

45.

Zhang, X. Zheng, Y. Liu, H. Yang, D. Zhou, D. Yu, J. Hou, Z. Shi, S. Chen, Z.
Chen, X. Zhang, X. Yang, Effectiveness of convalescent plasma therapy in
severe COVID-19 patients. Proc Natl Acad Sci U S A 117, 9490-9496 (2020).
M. J. Joyner, R. S. Wright, D. Fairweather, J. W. Senefeld, K. A. Bruno, S. A.
Klassen, R. E. Carter, A. M. Klompas, C. C. Wiggins, J. R. Shepherd, R. F. Rea,
E. R. Whelan, A. J. Clayburn, M. R. Spiegel, P. W. Johnson, E. R. Lesser, S.
E. Baker, K. F. Larson, J. G. Ripoll, K. J. Andersen, D. O. Hodge, K. L. Kunze,
M. R. Buras, M. N. Vogt, V. Herasevich, J. J. Dennis, R. J. Regimbal, P. R.
Bauer, J. E. Blair, C. M. van Buskirk, J. L. Winters, J. R. Stubbs, N. S. Paneth,
N. C. Verdun, P. Marks, A. Casadevall, Early safety indicators of COVID-19
convalescent plasma in 5,000 patients. J Clin Invest, (2020).
C. Shen, Z. Wang, F. Zhao, Y. Yang, J. Li, J. Yuan, F. Wang, D. Li, M. Yang, L.
Xing, J. Wei, H. Xiao, Y. Yang, J. Qu, L. Qing, L. Chen, Z. Xu, L. Peng, Y. Li,
H. Zheng, F. Chen, K. Huang, Y. Jiang, D. Liu, Z. Zhang, Y. Liu, L. Liu,
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA, (2020).
A. Agarwal, A. Mukherjee, G. Kumar, P. Chatterjee, T. Bhatnagar, P. Malhotra,
Convalescent plasma in the management of moderate covid-19 in adults in
India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ 371, m3939 (2020).
L. Li, W. Zhang, Y. Hu, X. Tong, S. Zheng, J. Yang, Y. Kong, L. Ren, Q. Wei,
H. Mei, C. Hu, C. Tao, R. Yang, J. Wang, Y. Yu, Y. Guo, X. Wu, Z. Xu, L. Zeng,
N. Xiong, L. Chen, J. Wang, N. Man, Y. Liu, H. Xu, E. Deng, X. Zhang, C. Li, C.
Wang, S. Su, L. Zhang, J. Wang, Y. Wu, Z. Liu, Effect of Convalescent Plasma
Therapy on Time to Clinical Improvement in Patients With Severe and Lifethreatening COVID-19: A Randomized Clinical Trial. JAMA, (2020).
V. A. Simonovich, L. D. Burgos Pratx, P. Scibona, M. V. Beruto, M. G. Vallone,
C. VÃ¡zquez, N. Savoy, D. H. Giunta, L. G. PÃ©rez, M. d. L. SÃ¡nchez, A. V.
Gamarnik, D. S. Ojeda, D. M. Santoro, P. J. Camino, S. Antelo, K. Rainero, G.
P. Vidiella, E. A. Miyazaki, W. Cornistein, O. A. Trabadelo, F. M. Ross, M. Spotti,
G. Funtowicz, W. E. Scordo, M. H. Losso, I. Ferniot, P. E. Pardo, E. Rodriguez,
P. Rucci, J. Pasquali, N. A. Fuentes, M. Esperatti, G. A. Speroni, E. C. Nannini,
A. Matteaccio, H. G. Michelangelo, D. Follmann, H. C. Lane, W. H. Belloso, A
Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
New England Journal of Medicine, (2020).
S. Chakraborty, J. Gonzalez, K. Edwards, V. Mallajosyula, A. S. Buzzanco, R.
Sherwood, C. Buffone, N. Kathale, S. Providenza, M. M. Xie, J. R. Andrews, C.
A. Blish, U. Singh, H. Dugan, P. C. Wilson, T. D. Pham, S. D. Boyd, K. C.
Nadeau, B. A. Pinsky, S. Zhang, M. J. Memoli, J. K. Taubenberger, T. Morales,
J. M. Schapiro, G. S. Tan, P. Jagannathan, T. T. Wang, Proinflammatory IgG
Fc structures in patients with severe COVID-19. Nature Immunology, (2020).
W. Hoepel, H.-J. Chen, S. Allahverdiyeva, X. Manz, J. Aman, P. Bonta, P.
Brouwer, S. de Taeye, T. Caniels, K. van der Straten, K. Golebski, G. Griffith,
R. Jonkers, M. Larsen, F. Linty, A. Neele, J. Nouta, F. van Baarle, C. van
Drunen, A. Vlaar, G. de Bree, R. Sanders, L. Willemsen, M. Wuhrer, H. J.
Bogaard, M. van Gils, G. Vidarsson, M. de Winther, J. den Dunnen, Anti-SARSCoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyperinflammatory responses. bioRxiv, 2020.2007.2013.190140 (2020).
F. P. Polack, M. N. Teng, P. L. Collins, G. A. Prince, M. Exner, H. Regele, D.
D. Lirman, R. Rabold, S. J. Hoffman, C. L. Karp, S. R. Kleeberger, M. Wills-

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721

46.
47.

48.

49.

50.

51.

Karp, R. A. Karron, A role for immune complexes in enhanced respiratory
syncytial virus disease. J Exp Med 196, 859-865 (2002).
F. P. Polack, Atypical measles and enhanced respiratory syncytial virus
disease (ERD) made simple. Pediatr Res 62, 111-115 (2007).
R. L. Tillett, J. R. Sevinsky, P. D. Hartley, H. Kerwin, N. Crawford, A. Gorzalski,
C. Laverdure, S. C. Verma, C. C. Rossetto, D. Jackson, M. J. Farrell, S. Van
Hooser, M. Pandori, Genomic evidence for reinfection with SARS-CoV-2: a
case study. The Lancet Infectious Diseases.
B. Prado-Vivar, M. Becerra-Wong, J. J. Guadalupe, S. Marquez, B. Gutierrez,
P. Rojas-Silva, M. Grunauer, G. Trueba, V. Barragan, P. Cardenas, COVID-19
Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First
Confirmed Event in South America. SSRN, (2020).
K. J. Selva, C. E. van de Sandt, M. M. Lemke, C. Y. Lee, S. K. Shoffner, B. Y.
Chua, T. H. O. Nguyen, L. C. Rowntree, L. Hensen, M. Koutsakos, C. Y. Wong,
D. C. Jackson, K. L. Flanagan, J. Crowe, A. C. Cheng, D. L. Doolan, F. Amanat,
F. Krammer, K. Chappell, N. Modhiran, D. Watterson, P. Young, B. Wines, P.
M. Hogarth, R. Esterbauer, H. G. Kelly, H.-X. Tan, J. A. Juno, A. K. Wheatley,
S. J. Kent, K. B. Arnold, K. Kedzierska, A. W. Chung, Distinct systems serology
features
in
children,
elderly
and
COVID
patients.
medRxiv,
2020.2005.2011.20098459 (2020).
B. D. Wines, H. M. Trist, R. C. Monteiro, C. Van Kooten, P. M. Hogarth, Fc
receptor gamma chain residues at the interface of the cytoplasmic and
transmembrane domains affect association with FcalphaRI, surface expression,
and function. J Biol Chem 279, 26339-26345 (2004).
P. A. Darrah, D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J.
Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, M. Roederer, R. A.
Seder, Multifunctional TH1 cells define a correlate of vaccine-mediated
protection against Leishmania major. Nat Med 13, 843-850 (2007).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

722

Acknowledgments

723

We thank the cohort participants for generously providing samples. We thank

724

Francesca Mordant and Kanta Subbarao (University of Melbourne) for performing the

725

SARS-CoV-2 neutralisation assays. We acknowledge the Melbourne Cytometry

726

Platform for provision of flow cytometry services. The following reagent was produced

727

under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH:

728

Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus

729

2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293F Cells,

730

NR-52366. This study was supported by the Victorian Government, an Australian

731

government Medical Research Future Fund award GNT2002073 (SJK, MPD, and

732

AKW), the ARC Centre of Excellence in Convergent Bio-Nano Science and

733

Technology (SJK), an NHMRC program grant APP1149990 (SJK and MPD), NHMRC

734

project grants GNT1162760 (AKW), GNT1145303 (PMH and BDW), an NHMRC-EU

735

collaborative award APP1115828 (SJK and MPD), the European Union Horizon 2020

736

Research and Innovation Programme under grant agreement 681137 (SJK), and

737

Emergent Ventures Fast Grants (AWC). JAJ, AWC and SJK are supported by NHMRC

738

fellowships. AKW, DC and MPD are supported by NHMRC Investigator grants.

739

Figures were created using BioRender.

740

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

741

Figures

A

Subject

FcÎ³R Binding (MFI)

B

S
10

6

10

5

FcÎ³RIIIa
t1/2 = 175 days

10

6

10

5

104

104

103

103

102

102

10

1

10

0

30

60

90

120

150

10

1

10

0

FcÎ³RIIa
t1/2 = 175 days

30

60

90

120

150

120

150

Days post-symptom onset

0

30

60

90

120

150

Days post-symptom onset
Samples for multiplex analysis
Samples for multiplex and functional
assay analysis

FcÎ³R Binding (MFI)

C

RBD
10

6

10

5

FcÎ³RIIIa
t1/2 = 95 days

10

6

10

5

104

104

103

103

102

102

10

1

10

0

30

60

90

120

150

10

1

10

0

FcÎ³RIIa
t1/2 = 74 days

30

60

90

Days post-symptom onset

742
743

Fig. 1. Dynamics of SARS-CoV-2 S and RBD-specific dimeric FcÎ³R-binding

744

antibodies in COVID-19 convalescent individuals. (A) Timeline of sample

745

collection for each COVID-19 convalescent subject (n=53). Subjects with 2 samples

746

at least 60 days apart were chosen for functional assay analysis (n=36). (B-C) Kinetics

747

of SARS-CoV-2 S and RBD-specific dimeric FcÎ³RIIIa (V158) and dimeric FcÎ³RIIa

748

(H131) binding antibodies over time. The best-fit decay slopes (red lines) and

749

estimated half-lives (t1/2) are indicated for COVID-19 convalescent individuals.

750

Uninfected controls (n=33) are shown in open circles, with the median and 90%

751

percentile responses presented as thick and thin dashed lines respectively. The limit

752

of detection is shown as the shaded area.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

A

B
NF-ÎºB-RE
nanoluciferase

NK cell

FcÎ³RIIIa

Plasma
Abs

A549
S-orange

****
6Ã—105
4Ã—105
2Ã—105
0

T1

105

104

103

102

T2

r = 0.78
p <0.0001
0

5

10
2Ã—

5

10
4Ã—

5

10
6Ã—

FcÎ³RIIIa dimer binding (MFI)

D

8Ã—105

Cell-associated
S-specific IgG (MFI)

FcÎ³RIIIa activation (AUC)

C

Ramos
S-luciferase

5

30000

20000

10000

0

10
8Ã—

r = 0.82
p <0.0001
0

E

F

80
60
40
20
0

753

Cell-associated
S-specific IgG (MFI)

ADCC (AUC)

****

T1

105

T2

104

103

102

r = 0.74
p <0.0001
0

20

40

60

ADCC (AUC)

80

5

10
4Ã—

5

10
6Ã—

5

10
8Ã—

FcÎ³RIIIa activation (AUC)
FcÎ³RIIIa dimer binding (MFI)

FcÎ³RIIIa activation (AUC)

5

10
2Ã—

30000

20000

10000

0

r = 0.78
p <0.0001
0

20
40
60
ADCC (AUC)

80

754

Fig. 2. ADCC responses in COVID-19 convalescent individuals over time. (A)

755

Schematic of the FcÎ³RIIIa NF-ÎºB activation assay. IIA1.6 cells expressing FcÎ³RIIIa

756

V158 and a NF-ÎºB response element-driven nanoluciferase reporter were co-

757

incubated with A549 S-orange target cells and plasma from COVID-19 convalescent

758

individuals or uninfected controls. The engagement of FcÎ³RIIIa by S-specific

759

antibodies activates downstream NF-ÎºB signalling and nano-luciferase expression. (B)

760

Schematic of the luciferase-based ADCC assay. Purified NK cells from healthy donors

761

were co-incubated with Ramos S-luciferase target cells and plasma. ADCC is

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

762

measured as the loss of cellular luciferase. (C) S-specific FcÎ³RIIIa-activating plasma

763

antibodies in COVID-19 convalescent individuals in the first (T1; filled) and last (T2;

764

open) timepoints available. (D) Correlation of S-specific FcÎ³RIIIa-activating antibodies

765

to cell-associated S-specific IgG and S-specific dimeric FcÎ³RIIIa-binding antibodies.

766

(E) S-specific ADCC mediated by plasma antibodies from COVID-19 convalescent

767

individuals in the first (T1; filled) and last (T2; open) timepoints available. (F)

768

Correlation of S-specific ADCC to cell-associated S-specific IgG and S-specific

769

dimeric FcÎ³RIIIa-binding antibodies. Red lines indicate the median responses of

770

COVID-19 convalescent individuals (N=36) while dashed lines indicate median

771

responses of uninfected controls (N=8). Statistical analyses were performed with the

772

Wilcoxon signed-rank test (****, p<0.0001). Correlations were performed with the non-

773

parametric Spearman test.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

A

B

THP-1 (monocyte)

FcÎ³RI
FcÎ³RIIa
Plasma Abs

60

D

**

Cell-associated
S-specific IgG (MFI)

Phagocytic score

C

40

20

0

T1

105

104

103

102

T2

r = 0.85
p <0.0001
0

20

40

FcÎ³RIIa dimer binding (MFI)

Ramos
S-orange

S-conjugated FITC
fluorescent beads

60

30000

20000

10000

0

r = 0.82
p <0.0001
0

Cell-associated
S-specific IgG (MFI)

%Association

**
30
20
10
0
T1

774

T2

105

104

103

102

r = 0.85
p <0.0001
0

10

20

30

%Association

40

FcÎ³RIIa dimer binding (MFI)

F

40

40

60

Phagocytic score

Phagocytic score

E

20

30000

20000

10000

0

r = 0.80
p <0.0001
0

10

20

30

40

%Association

775
776

Fig. 3. ADP responses in COVID-19 convalescent individuals over time. (A)

777

Schematic of the bead-based ADP assay. THP-1 cells were incubated with S-

778

conjugated fluorescent beads and plasma from COVID-19 convalescent individuals or

779

uninfected controls. The uptake of fluorescent beads was measured by flow cytometry

780

(B) Schematic of the THP-1 FcÎ³R-dependent cell association assay. Ramos S-orange

781

cells were pre-incubated with plasma prior to co-incubation with THP-1 cells. The

782

association of THP-1 cells with Ramos S-orange cells was measured by flow

783

cytometry. (C) ADP of S-conjugated beads mediated by plasma antibodies from

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

784

COVID-19 convalescent individuals in the first (T1) and last (T2) timepoints available.

785

(D) Correlation of ADP to cell-associated S-specific IgG and S-specific dimeric

786

FcÎ³RIIa-binding antibodies. (E) FcÎ³R-dependent association of THP-1 cells with

787

Ramos S-orange cells mediated by plasma antibodies from COVID-19 convalescent

788

individuals in the first (T1) and last (T2) timepoints available. (F) Correlation of

789

association of THP-1 cells with Ramos S-orange cells to cell-associated S-specific IgG

790

and S-specific dimeric FcÎ³RIIIa-binding antibodies. Red lines indicate the median

791

responses of COVID-19 convalescent individuals (N=36) while dashed lines indicate

792

median responses of uninfected controls (N=8). Statistical analyses were performed

793

with the Wilcoxon signed-rank test (**, p<0.01). Correlations were performed with the

794

non-parametric Spearman test.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

A

IgG

FcÎ³RIIIa

FcÎ³RIIa

100

100

90

90

90

80

80

80

70

70

%Change

100

70

60

OC43 S
HKU1 S
229E S
NL63 S
30

60

90

120

150

60

30

60

90

120

150

60

30

60

90

120

150

Days post-symptom onset

B

OC43 S

OC43 S1

6

10

t1/2 = 224 days

105

105

4

10

10

3

10

3

10

10

2

10

2

10
10

10

0

10

6

1033

60

90

120

150

t1/2 = 171 days

10

0

10

6

2

2

1

101
10

101
30

00

30

60

90

120

150

10
10
10

t1/2 = ns

105
4

10

4

10

3

10

3

10

3

10

2

10

2

10

2

101
60

90

120

150

10

90

120

150

t1/2 = 179 days

10

30

60

105

4

0

30
30

6

10

10

t1/2 = 229 days

1044

10

101

795
796

105

t1/2 = ns

4

105

FcÎ³RIIa

10

105

101

OC43 S2

1066

6

10

FcÎ³R Binding (MFI)

FcÎ³RIIIa

FcÎ³R Binding (MFI)

10

101

0

30

60

90

120

150

10

0

30

60

90

120

150

Days post-symptom onset

797

Fig. 4. Dynamics of HCoV S-specific antibodies in COVID-19 convalescent

798

individuals. (A) Best fit decay slopes of IgG and dimeric FcÎ³R-binding antibodies

799

against S from HCoV strains OC43, HKU1, 229E and NL63. The responses at

800

timepoint 1 for each parameter are set to 100% and the %change over time is shown.

801

(B-C) Kinetics of dimeric FcÎ³RIIIa (V158) and FcÎ³RIIa (H131) binding antibodies

802

against HCoV-OC43 S antigens over time in COVID-19 convalescent individuals

803

(n=53). The best-fit decay slopes (red lines) and estimated half-lives (t1/2) are indicated

medRxiv preprint doi: https://doi.org/10.1101/2020.12.13.20248143; this version posted December 14, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

804

for COVID-19 convalescent individuals. Uninfected controls (n=33) are shown in open

805

circles, with the median and 90% percentile responses presented as thick and thin

806

dashed lines respectively. The limit of detection is shown as the shaded area.

807
808
B
100

100

80

80

100

C
C

A

lis
a

as
1
P-

Fc
Î³

R

eu
tr
a
N

D
P
so
ci
at
io
n

0

150

Days post-symptom onset

809
810

100

TH

120

94

D

90

97

A

60

70

tio
n

30

20

tiv
a

0

40

tio
n

20

Cell-associated S IgG
FcÎ³RIIIa-binding to anti-S Ab
FcÎ³RIIa-binding to anti-S Ab
FcÎ³RIIIa activation
ADCC
ADP
THP-1 association with S-expressing cells
Neutralisation
S-specific IgG

60

ac

40

Undetectable
Detectable
at last visit

III
a

60

% of subjects

%Change

A

811

Fig. 5. Decay kinetics of binding antibodies, neutralisation and Fc effector

812

functions following SARS-CoV-2 infection. (A) Best fit decay slopes of various

813

antibody parameters against SARS-CoV-2 S over time. The responses at timepoint 1

814

for each parameter are set to 100% and the %change over time is shown. (B) The

815

percentage of subjects having detectable responses above (red) and below (grey)

816

background levels at the last visit are shown. Background levels for each assay were

817

the median responses of uninfected controls.

818

